Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Prostate Cancer - Identifying
and Commercializing First-in-Class Innovation
Single User License - 6995 Site User
License - 13990 Corporate User License -
20985 Publication Date - Nov 2014 Pages -
91 To know more details, email to
debora_at_reportstack.com
2
Summary

• The prostate cancer pipeline is among the largest
  in the pharmaceutical industry with 484 products
  in active development across all stages. The
  range of mechanisms of action employed by these
  compounds is also highly diverse, especially in
  comparison to the existing market landscape. More
  pertinently, the degree and proportion of
  breakthrough innovations in this pipeline is
  exceptional The Research analysis identified 174
  first-in-class programs in the prostate cancer
  pipeline, acting on 122 first-in-class molecular
  targets. This accounts for some 36 of all
  products with a disclosed molecular target and is
  reflective of the high degree of innovation in
  this indication.

3
Scope
- A brief introduction to prostate cancer,
including symptoms, pathophysiology, and overview
of pharmacotherapy and treatment algorithms.-
The changing molecular target landscape between
market and pipeline and particular focal points
of innovation in the pipeline.- Comprehensive
review of the pipeline for first-in-class
therapies, analyzed on the basis of stage of
development, molecule type and molecular
target.- Identification and assessment of
first-in-class molecular targets with a
particular focus on early-stage programs of which
clinical utility has yet to be evaluated, as well
as literature reviews on novel molecular
targets.- Assessment of the licensing and
co-development deal landscape for prostate cancer
therapies and benchmarking of deals involving
first-in-class versus non-first-in-class-products.
4
Key Benefits
- Understanding of the focal shifts in molecular
targets in the prostate cancer pipeline.-
Understanding of the distribution of pipeline
programs by phase of development, molecule type
and molecular target.- Access a scientific and
clinical analysis of first-in-class developmental
programs for prostate cancer, benchmarked against
non-first-in-class targets.- Access a list of
the first-in-class therapies potentially open to
deal-making opportunities
5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com